IR@PKUHSC  > 北京大学基础医学院  > 细胞生物学系
学科主题基础医学
LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma
Yang, Hua1; Xiong, Fu Xia1; Lin, Ming1; Yang, Yu2; Nie, Xiu3; Zhou, Rou Li1
关键词Lysosomal protein transmembrane 4 beta Immunohistochemistry HCC Recurrence Survival
刊名JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2010-02-01
DOI10.1007/s00432-009-0659-4
136期:2页:275-281
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]MULTIDRUG-RESISTANCE ; MEMBRANE-PROTEIN ; EXPRESSION ; SURVIVAL ; INVASION ; MARKER ; KINASE ; AKT
英文摘要

Lysosomal protein transmembrane 4 beta-35 (LAPTM4B-35) is a tetra-transmembrane glycoprotein that is abundantly localized on membrane-bound organelles including endosomes and lysosomes, and promotes cell proliferation and tumorigenesis through regulation of cell cycle and signaling pathways. The aim of the present study is to determine the potential clinical implications of LAPTM4B-35 expression in hepatocellular carcinoma (HCC).

Immunohistochemistry assay was used to determine the expression of LAPTM4B-35 protein in normal and HCC tissues from 71 patients. The correlations of LAPTM4B-35 expression with clinicopathological parameters, including gender, age, background liver, viral status, tumor size, portal vein invasion, histopathological differentiation, serum AFP level, TNM staging and recurrence of HCC were assessed by Chi-squared test. Patient survival and their differences were determined by Kaplan-Meier method and log-rank test. Cox regression (Proportional hazard model) was adopted for multivariate analysis of prognostic factors.

LAPTM4B-35 immunoreactivity was negative or low in normal liver tissues, but high in HCC tissues (51/71, 71.8%). The overexpression of LAPTM4B-35 was significantly associated with recurrence, TNM staging and portal vein invasion of HCC. Patients with high LAPTM4B-35 expression had significantly poorer overall survival (OS) and disease-free survival (DFS) (both P < 0.001) when compared with patients with the low expression of LAPTM4B-35. On multivariate analysis, LAPTM4B-35 expression was found to be an independent prognostic factor for OS and DFS (P = 0.018 and P = 0.001, respectively).

LAPTM4B-35 expression showed a strong association with the potencies of recurrence and metastasis and progression of HCC, and that may be applied as a novel marker for the prediction of recurrence and metastasis potency of HCC, and helpful for improving the diagnosis, prognosis and treatment of HCC.

语种英语
WOS记录号WOS:000273033100013
引用统计
被引频次:45[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59759
专题北京大学基础医学院_细胞生物学系
作者单位1.Peking Univ, Dept Cell Biol, Sch Basic Med Sci, Beijing 100191, Peoples R China
2.Childrens Natl Med Ctr, Ctr Mol Physiol Res, Washington, DC 20010 USA
3.Huazhong Univ Sci & Technol, Dept Pathol, Union Hosp Affiliated, Tongji Med Coll, Wuhan 430022, Peoples R China
推荐引用方式
GB/T 7714
Yang, Hua,Xiong, Fu Xia,Lin, Ming,et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,2010,136(2):275-281.
APA Yang, Hua,Xiong, Fu Xia,Lin, Ming,Yang, Yu,Nie, Xiu,&Zhou, Rou Li.(2010).LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,136(2),275-281.
MLA Yang, Hua,et al."LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma".JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136.2(2010):275-281.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang, Hua]的文章
[Xiong, Fu Xia]的文章
[Lin, Ming]的文章
百度学术
百度学术中相似的文章
[Yang, Hua]的文章
[Xiong, Fu Xia]的文章
[Lin, Ming]的文章
必应学术
必应学术中相似的文章
[Yang, Hua]的文章
[Xiong, Fu Xia]的文章
[Lin, Ming]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。